| Obesity |
1 |
1 |
| Weight Loss |
0 |
0.87 |
| Bariatric Surgery |
0 |
0.84 |
| Weight Management |
0 |
0.7 |
| GLP-1 Receptor Agonist |
0 |
0.34 |
| Lipids Management |
0 |
0.34 |
| Receptors |
0 |
0.31 |
| Biliary Disease |
0 |
0.19 |
| Cardiovascular Risk Management |
0 |
0.18 |
| Arrhythmia |
0 |
0.15 |
| Clinical Research |
0 |
0.15 |
| Plasma |
0 |
0.15 |
| Non-Alcoholic Fatty Liver Disease |
0 |
0.13 |
| Healthcare and Medical Technology |
0 |
0.12 |
| Fatty Liver |
0 |
0.11 |
| High Density Lipoprotein (HDL) cholesterol |
0 |
0.11 |
| LDL Cholesterol |
0 |
0.11 |
| Liver Disease |
0 |
0.11 |
| Adverse Effects |
0 |
0.1 |
| Incretin Hormone |
0 |
0.1 |
| Lipoproteins |
0 |
0.1 |
| Liver |
0 |
0.1 |
| Metabolic Syndrome |
0 |
0.1 |
| New York |
0 |
0.1 |
| PCSK9 |
0 |
0.1 |
| Physiology |
0 |
0.1 |
| Patient Safety |
0 |
0.08 |
| Type 2 Diabetes Mellitus |
0 |
0.08 |
| Cardiometabolic Risk Factors |
0 |
0.07 |
| Hypertension |
0 |
0.07 |